Related Experiment Videos
A fully integrated protein crystallization platform for small-molecule drug discovery
David Hosfield1, John Palan, Mark Hilgers
1Syrrx, Inc., 10410 Science Center Drive, San Diego, CA 92121, USA.
Journal of Structural Biology
|April 30, 2003
Summary
Syrrx developed a cost-efficient platform for structure-based drug discovery, enhancing the crystallization of challenging protein targets. This method accelerates the identification of potential small-molecule drugs by optimizing protein crystallization trials.
Area of Science:
- Biochemistry
- Structural Biology
- Drug Discovery
Background:
- Structure-based drug discovery requires efficient methods for crystallizing protein targets.
- Refractory protein targets pose significant challenges in drug discovery pipelines.
- Cost-efficiency and speed are critical for assessing target feasibility.
Purpose of the Study:
- To describe a novel platform for structure-based drug discovery.
- To detail a method for enhancing the crystallization of difficult protein targets.
- To support a small-molecule drug discovery program through optimized crystallization.
Main Methods:
- Coupling construct and purification diversity with nanovolume crystallization.
- Executing millions of crystallization and imaging trials.
- Utilizing a platform developed by the Structural Biology Group at Syrrx.
Main Results:
- The platform successfully supported a small-molecule drug discovery program.
- Over 400 unique drug-discovery targets were assessed.
- Millions of crystallization and imaging trials were performed over 18 months.
Conclusions:
- The developed platform is effective for structure-based drug discovery.
- The methodology allows for rapid assessment of protein crystallization feasibility.
- The platform optimizes drug discovery by improving crystallization success rates for challenging targets.